Medicine Overview

Indication

Details coming soon

Know Medicine, Follow Guideline

Details coming soon

Adult Dose

Clinical InformationAdministration Information
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Age: 2 through 55 years
Dose: Intramuscular injection – 0.5 mL
Frequency: Single dose
Note: Primary Vaccination
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Age: 15 through 55 years
Condition: At continued risk for meningococcal disease
Dose: Intramuscular injection – Single booster dose
Note: Booster Vaccination; may be given if at least 4 years have elapsed since the prior dose

Child Dose

Clinical InformationAdministration Information
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Age: Children 9 through 23 months of age
Dose: Intramuscular injection – Two doses
Frequency: three months apart
Note: Primary Vaccination
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Age: individuals 15 through 55 years of age
Condition: at continued risk for meningococcal disease
Dose: Intramuscular injection – 0.5 mL
Note: Booster Vaccination; a single booster dose may be given if at least 4 years have elapsed since the prior dose
Administration

Administer as a 0.5 mL intramuscular injection, preferably into the anterolateral aspect of the thigh for infants and the deltoid muscle for older children and adults. For Menveo, reconstitute the lyophilized MenA component with the liquid MenCYW-135 component and shake well; Menactra and MenQuadfi are supplied as ready-to-use solutions. Dosing schedules vary by age and product: infants may require a 2-dose or 4-dose primary series starting as early as 6 weeks, while individuals 2 years and older typically receive a single dose. Booster doses are recommended for those at continued high risk. Do not administer intravenously, subcutaneously, or intradermally. Syncope may occur following vaccination; observe patients for 15 minutes post-injection. This vaccine should not be given to individuals with a history of severe allergic reaction to any vaccine component or previous dose.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.